Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kala Bio, Inc. (KALA) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kala Bio, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1479419.
Total stock buying since 2017: $211,974,897.
Total stock sales since 2017: $2,805,643.
Total stock option exercises since 2017: $732,803.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 55,280 | $269,270 | 0 | $0 |
| 2024 | 310,559 | $1,999,999 | 59,535 | $323,505 | 0 | $0 |
| 2023 | 0 | $0 | 453 | $12,926 | 0 | $0 |
| 2022 | 0 | $0 | 3,876,827 | $1,892,322 | 0 | $0 |
| 2021 | 0 | $0 | 123,828 | $307,620 | 9,500 | $21,850 |
| 2020 | 15,219,166 | $120,057,818 | 0 | $0 | 171,149 | $495,737 |
| 2019 | 5,000 | $27,100 | 0 | $0 | 4,824 | $2,773 |
| 2018 | 6,450,153 | $59,424,995 | 0 | $0 | 9,769 | $22,175 |
| 2017 | 2,030,999 | $30,464,985 | 0 | $0 | 108,725 | $190,268 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 0 | $0 | 41,335 | $162,873 | 0 | $0 |
| 2025-01 | 0 | $0 | 13,945 | $106,397 | 0 | $0 |
| 2024-12 | 310,559 | $1,999,999 | 0 | $0 | 0 | $0 |
| 2024-06 | 0 | $0 | 34,631 | $164,495 | 0 | $0 |
| 2024-05 | 0 | $0 | 13,504 | $82,237 | 0 | $0 |
| 2024-01 | 0 | $0 | 11,400 | $76,773 | 0 | $0 |
| 2023-01 | 0 | $0 | 453 | $12,926 | 0 | $0 |
| 2022-10 | 0 | $0 | 214 | $1,393 | 0 | $0 |
| 2022-06 | 0 | $0 | 19,437 | $7,189 | 0 | $0 |
| 2022-05 | 0 | $0 | 3,835,000 | $1,854,912 | 0 | $0 |
| 2022-01 | 0 | $0 | 22,176 | $28,828 | 0 | $0 |
| 2021-10 | 0 | $0 | 102,297 | $184,553 | 0 | $0 |
| 2021-06 | 0 | $0 | 21,531 | $123,067 | 0 | $0 |
| 2021-03 | 0 | $0 | 0 | $0 | 9,500 | $21,850 |
| 2020-10 | 40 | $304 | 0 | $0 | 0 | $0 |
| 2020-06 | 2 | $26 | 0 | $0 | 72,378 | $281,644 |
| 2020-04 | 0 | $0 | 0 | $0 | 67,771 | $142,793 |
| 2020-03 | 15,219,124 | $120,057,488 | 0 | $0 | 31,000 | $71,300 |
| 2019-08 | 0 | $0 | 0 | $0 | 4,824 | $2,773 |
| 2019-05 | 5,000 | $27,100 | 0 | $0 | 0 | $0 |
| 2018-10 | 5,454,544 | $44,999,987 | 0 | $0 | 0 | $0 |
| 2018-02 | 85,680 | $1,223,004 | 0 | $0 | 9,769 | $22,175 |
| 2018-01 | 909,929 | $13,202,004 | 0 | $0 | 0 | $0 |
| 2017-08 | 0 | $0 | 0 | $0 | 108,725 | $190,268 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-24 | Kharabi Darius (CHIEF BUSINESS OFFICER) | Sale | 4,511 | 4.01 | 18,089 |
| 2025-06-24 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 3,631 | 4.01 | 14,560 |
| 2025-06-24 | Bazemore Todd (SEE REMARKS) | Sale | 4,058 | 4.01 | 16,272 |
| 2025-06-24 | Iwicki Mark T | Sale | 13,227 | 4.01 | 53,040 |
| 2025-06-24 | Brazzell Romulus K (SEE REMARKS) | Sale | 5,251 | 4.01 | 21,056 |
| 2025-06-03 | Kharabi Darius (CHIEF BUSINESS OFFICER) | Sale | 730 | 3.74 | 2,730 |
| 2025-06-03 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 2,850 | 3.74 | 10,659 |
| 2025-06-03 | Bazemore Todd (SEE REMARKS) | Sale | 3,390 | 3.74 | 12,678 |
| 2025-06-03 | Brazzell Romulus K (SEE REMARKS) | Sale | 3,687 | 3.74 | 13,789 |
| 2025-01-06 | Kharabi Darius (CHIEF BUSINESS OFFICER) | Sale | 2,021 | 7.63 | 15,420 |
| 2025-01-06 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 1,706 | 7.63 | 13,016 |
| 2025-01-06 | Bazemore Todd (SEE REMARKS) | Sale | 1,993 | 7.63 | 15,206 |
| 2025-01-06 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 5,779 | 7.63 | 44,093 |
| 2025-01-06 | Brazzell Romulus K (SEE REMARKS) | Sale | 2,446 | 7.63 | 18,662 |
| 2024-12-30 | Baker Julian | Buy | 310,559 | 6.44 | 1,999,999 |
| 2024-06-26 | Kharabi Darius (CHIEF BUSINESS OFFICER) | Sale | 5,158 | 4.75 | 24,500 |
| 2024-06-26 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 4,163 | 4.75 | 19,774 |
| 2024-06-26 | Bazemore Todd (SEE REMARKS) | Sale | 4,653 | 4.75 | 22,101 |
| 2024-06-26 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 15,168 | 4.75 | 72,048 |
| 2024-06-26 | Brazzell Romulus K (SEE REMARKS) | Sale | 5,489 | 4.75 | 26,072 |
| 2024-05-31 | Kharabi Darius (CHIEF BUSINESS OFFICER) | Sale | 231 | 6.09 | 1,406 |
| 2024-05-31 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 1,786 | 6.09 | 10,876 |
| 2024-05-31 | Bazemore Todd (SEE REMARKS) | Sale | 2,093 | 6.09 | 12,746 |
| 2024-05-31 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 7,392 | 6.09 | 45,017 |
| 2024-05-31 | Brazzell Romulus K (SEE REMARKS) | Sale | 2,002 | 6.09 | 12,192 |
| 2024-01-04 | Kharabi Darius (CHIEF BUSINESS OFFICER) | Sale | 1,385 | 6.73 | 9,321 |
| 2024-01-04 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 1,227 | 6.74 | 8,269 |
| 2024-01-04 | Trachtenberg Eric (SEE REMARKS) | Sale | 1,227 | 6.74 | 8,269 |
| 2024-01-04 | Bazemore Todd (SEE REMARKS) | Sale | 1,405 | 6.74 | 9,469 |
| 2024-01-04 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 4,539 | 6.73 | 30,547 |
| 2024-01-04 | Brazzell Romulus K (SEE REMARKS) | Sale | 1,617 | 6.74 | 10,898 |
| 2023-01-04 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 60 | 28.54 | 1,712 |
| 2023-01-04 | Trachtenberg Eric (SEE REMARKS) | Sale | 60 | 28.55 | 1,713 |
| 2023-01-04 | Bazemore Todd (SEE REMARKS) | Sale | 62 | 28.54 | 1,769 |
| 2023-01-04 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 198 | 28.54 | 5,650 |
| 2023-01-04 | Brazzell Romulus K (SEE REMARKS) | Sale | 73 | 28.53 | 2,082 |
| 2022-10-26 | Bazemore Todd (SEE REMARKS) | Sale | 214 | 6.51 | 1,393 |
| 2022-06-27 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 2,613 | .37 | 966 |
| 2022-06-27 | Trachtenberg Eric (SEE REMARKS) | Sale | 2,613 | .37 | 966 |
| 2022-06-27 | Bazemore Todd (SEE REMARKS) | Sale | 3,092 | .37 | 1,144 |
| 2022-06-27 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 7,975 | .37 | 2,950 |
| 2022-06-27 | Brazzell Romulus K (SEE REMARKS) | Sale | 3,144 | .37 | 1,163 |
| 2022-05-26 | Shah Rajeev M. | Sale | 1,005,686 | .36 | 366,069 |
| 2022-05-25 | Shah Rajeev M. | Sale | 1,434,509 | .42 | 602,493 |
| 2022-05-24 | Shah Rajeev M. | Sale | 144,805 | .51 | 73,850 |
| 2022-05-23 | Shah Rajeev M. | Sale | 1,250,000 | .65 | 812,500 |
| 2022-01-04 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 2,850 | 1.30 | 3,705 |
| 2022-01-04 | Trachtenberg Eric (SEE REMARKS) | Sale | 2,850 | 1.30 | 3,705 |
| 2022-01-04 | Bazemore Todd (SEE REMARKS) | Sale | 3,454 | 1.30 | 4,490 |
| 2022-01-04 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 9,518 | 1.30 | 12,373 |
| 2022-01-04 | Brazzell Romulus K (SEE REMARKS) | Sale | 3,504 | 1.30 | 4,555 |
| 2021-10-27 | Chen Hongming (CHIEF SCIENTIFIC OFFICER) | Sale | 21,051 | 1.82 | 38,312 |
| 2021-10-26 | Reumuth Mary (CHIEF FINANCIAL OFFICER) | Sale | 9,449 | 1.80 | 17,008 |
| 2021-10-26 | Chen Hongming (CHIEF SCIENTIFIC OFFICER) | Sale | 9,449 | 1.80 | 17,008 |
| 2021-10-26 | Trachtenberg Eric (SEE REMARKS) | Sale | 9,449 | 1.80 | 17,008 |
| 2021-10-26 | Bazemore Todd (CHIEF OPERATING OFFICER) | Sale | 12,544 | 1.80 | 22,579 |
| 2021-10-26 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 27,598 | 1.80 | 49,676 |
| 2021-10-26 | Brazzell Romulus K (CHIEF MEDICAL OFFICER) | Sale | 12,757 | 1.80 | 22,962 |
| 2021-06-29 | Chen Hongming (CHIEF SCIENTIFIC OFFICER) | Sale | 5,548 | 5.56 | 30,846 |
| 2021-06-28 | Trachtenberg Eric (SEE REMARKS) | Sale | 2,452 | 5.77 | 14,148 |
| 2021-06-28 | Bazemore Todd (CHIEF OPERATING OFFICER) | Sale | 2,911 | 5.77 | 16,796 |
| 2021-06-28 | Iwicki Mark T (CHIEF EXECUTIVE OFFICER) | Sale | 7,586 | 5.77 | 43,771 |
| 2021-06-28 | Brazzell Romulus K (CHIEF MEDICAL OFFICER) | Sale | 3,034 | 5.77 | 17,506 |
| 2021-03-01 | Chen Hongming (Chief Scientific Officer) | Option Ex | 9,500 | 2.30 | 21,850 |
| 2020-10-22 | Bazemore Todd (Chief Operating Officer) | Buy | 40 | 7.60 | 304 |
| 2020-06-19 | Trachtenberg Eric (See Remarks) | Option Ex | 28,901 | 5.19 | 149,996 |
| 2020-06-09 | Reumuth Mary (Chief Financial Officer) | Option Ex | 43,477 | 3.03 | 131,648 |
| 2020-06-05 | Bazemore Todd (Chief Operating Officer) | Buy | 2 | 13.39 | 26 |
| 2020-04-09 | Brazzell Romulus K (Chief Medical Officer) | Option Ex | 67,771 | 2.11 | 142,793 |
| 2020-03-30 | Chen Hongming (Chief Scientific Officer) | Option Ex | 31,000 | 2.30 | 71,300 |
| 2020-03-16 | Bazemore Todd (Chief Operating Officer) | Buy | 10,000 | 5.75 | 57,500 |
| 2020-03-13 | Grunberg Gregory | Buy | 2,534,854 | 7.89 | 19,999,998 |
| 2020-03-13 | Shah Rajeev M. | Buy | 6,337,135 | 7.89 | 49,999,995 |
| 2020-03-13 | Kolchinsky Peter | Buy | 6,337,135 | 7.89 | 49,999,995 |
| 2019-08-19 | Rosen Howard B (Director) | Option Ex | 4,824 | .57 | 2,773 |
| 2019-05-30 | Rosen Howard B (Director) | Buy | 5,000 | 5.42 | 27,100 |
| 2018-10-05 | Grunberg Gregory | Buy | 606,060 | 8.25 | 4,999,995 |
| 2018-10-03 | Shah Rajeev M. | Buy | 2,424,242 | 8.25 | 19,999,996 |
| 2018-10-03 | Kolchinsky Peter | Buy | 2,424,242 | 8.25 | 19,999,996 |
| 2018-02-28 | Chen Hongming (Chief Scientific Officer) | Option Ex | 9,769 | 2.27 | 22,175 |
| 2018-02-08 | Orbimed Capital Gp Vi Llc | Buy | 25,000 | 12.93 | 323,250 |
| 2018-02-02 | Orbimed Capital Gp Vi Llc | Buy | 37,840 | 14.73 | 557,383 |
| 2018-02-01 | Orbimed Capital Gp Vi Llc | Buy | 22,840 | 14.99 | 342,371 |
| 2018-01-31 | Orbimed Capital Gp Vi Llc | Buy | 339,400 | 15.00 | 5,091,000 |
| 2018-01-29 | Orbimed Capital Gp Vi Llc | Buy | 50,000 | 14.99 | 749,500 |
| 2018-01-26 | Orbimed Capital Gp Vi Llc | Buy | 22,760 | 14.93 | 339,806 |
| 2018-01-24 | Orbimed Capital Gp Vi Llc | Buy | 64,637 | 14.91 | 963,737 |
| 2018-01-23 | Orbimed Capital Gp Vi Llc | Buy | 4,363 | 14.99 | 65,401 |
| 2018-01-22 | Orbimed Capital Gp Vi Llc | Buy | 75,000 | 14.98 | 1,123,500 |
| 2018-01-19 | Orbimed Capital Gp Vi Llc | Buy | 74,931 | 14.95 | 1,120,218 |
| 2018-01-12 | Orbimed Capital Gp Vi Llc | Buy | 38,354 | 14.50 | 556,133 |
| 2018-01-12 | Isaly Samuel D | Buy | 28,446 | 15.40 | 438,068 |
| 2018-01-11 | Isaly Samuel D | Buy | 41,700 | 13.65 | 569,205 |
| 2018-01-10 | Isaly Samuel D | Buy | 170,338 | 12.83 | 2,185,436 |
| 2017-08-11 | Brazzell Romulus K (Chief Medical Officer) | Option Ex | 108,725 | 1.75 | 190,268 |
| 2017-07-25 | Grunberg Gregory | Buy | 215,000 | 15.00 | 3,225,000 |
| 2017-07-25 | Shah Rajeev M. | Buy | 533,333 | 15.00 | 7,999,995 |
| 2017-07-25 | Longitude Venture Partners Ii, L.p. (10% Owner) | Buy | 215,000 | 15.00 | 3,225,000 |
| 2017-07-25 | Kolchinsky Peter | Buy | 533,333 | 15.00 | 7,999,995 |
| 2017-07-25 | Isaly Samuel D | Buy | 319,333 | 15.00 | 4,789,995 |
| 2017-07-20 | Kovner Bruce | Buy | 215,000 | 15.00 | 3,225,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of KALA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kala Bio, Inc. (symbol KALA, CIK number 1479419) see the Securities and Exchange Commission (SEC) website.